Surface Oncology (NASDAQ:SURF) Receives “Buy” Rating from Jonestrading
Surface Oncology (NASDAQ:SURF – Get Assessment)The stock had its “buy” rating reissued by Jonestrading in a research note published on Sunday, reports TipRanks. They currently have a target price of $12.00 on the stock.
Several other research analysts have also published reports on the company. TheStreet downgraded Surface Oncology from a “c-” grade to a “d” grade in a Monday, March 7 research report. HC Wainwright reiterated a “buy” rating and set a target price of $10.00 on shares of Surface Oncology in a Thursday, March 3 research report. Finally, Zacks Investment Research downgraded Surface Oncology from a “buy” rating to a “hold” rating in a Thursday, May 5 research report. One research analyst has rated the stock with a hold rating and three have assigned the stock a buy rating. According to MarketBeat.com, Surface Oncology currently has a consensus rating of “Buy” and an average target price of $10.38.
SURF advanced $0.08 on Friday, hitting $1.93. The company had a trading volume of 928,511 shares, compared to an average volume of 714,196. The company has a market capitalization of $105.40 million, a PE ratio of -1.52 and a beta of 1.69. Surface Oncology has a 12-month low of $1.69 and a 12-month high of $9.37. The company has a quick ratio of 9.42, a current ratio of 9.42 and a leverage ratio of 0.17. The company’s 50-day simple moving average is $2.28 and its 200-day simple moving average is $3.51.
Surface Oncology (NASDAQ:SURF – Get Rating) last reported quarterly results on Monday, May 9. The company reported EPS of $0.13 for the quarter, beating the consensus estimate of ($0.48) by $0.61. The company recorded revenue of $30.00 million during the quarter. Surface Oncology posted a negative return on equity of 41.62% and a negative net margin of 182.63%. On average, analysts expect Surface Oncology to post -1.19 earnings per share for the current fiscal year.
A number of large investors have recently changed their stock holdings. BNP Paribas Arbitrage SA increased its position in Surface Oncology shares by 134.6% during the third quarter. BNP Paribas Arbitrage SA now owns 8,218 shares in the company worth $62,000 after purchasing an additional 4,715 shares last quarter. Russell Investments Group Ltd. acquired a new position in Surface Oncology stock during the first quarter worth $27,000. Citigroup Inc. increased its position in Surface Oncology shares by 62.8% during the fourth quarter. Citigroup Inc. now owns 10,553 shares of the company worth $50,000 after buying 4,071 additional shares in the last quarter. Spire Wealth Management acquired a new position in shares of Surface Oncology during the fourth quarter worth $53,000. Finally, Formidable Asset Management LLC acquired a new position in shares of Surface Oncology during the first quarter worth $33,000. 70.81% of the shares are held by institutional investors.
About Surface Oncology (Get a rating)
Surface Oncology, Inc, a clinical-stage immuno-oncology company, is engaged in the development of cancer therapies in the United States. The Company is developing various antibodies, including NZV930, a fully human immunoglobulin G4 isotype monoclonal antibody for extracellular adenosine production; SRF617, a fully human IgG4 monoclonal antibody that inhibits the enzymatic activity of CD39 for the production of adenosine and the degradation of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the CCR8 chemokine receptor.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in superficial oncology right now?
Before you consider surface oncology, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes hold…and Surface Oncology wasn’t on the list.
Although Surface Oncology currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here